The following records were provided by KEI from UCLA on September 28, 2018, following a freedom of Records Request. This page describes the contents of on very large PDF file, the “Combined IN Writ Petition DHC,” which is 1,309 pages long,… Continue Reading
This October 11, 2017 email, from Catherine Robinson of Pfizer to Daniel Watson and John Meile of USTR, asks USTR to block a competitor from a tender to sell a drug. USTR provides one email and redacts details including the… Continue Reading
The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading
KEI has received Pfizer and USTR emails and a Pfizer briefing memo to USTR from September 2017, asking the USTR to block a Malaysia Requirement to disclose drug prices. The documents were obtained under a Freedom of Information request to… Continue Reading
Sanofi $9.3 Billion Medivation Bid 28 April 2016. Ben Hirschler and Leigh Thomas. Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation. Reuters. 28 April 2016. Helen Thomas. Sanofi / Medivation: Deal-Making Déjà Vu Comes With Added Competition. WSJ.… Continue Reading
September 3, 2011 From KEI staff review of Wikileaks cables (/wikileaks) On May 14, 2008, The US Embassy in Warsaw sent a cable that discussed additions to the list of pharmaceutical products reimbursed by the government. A few highlights from… Continue Reading
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.